Report Highlights

HIV Drugs in the United States: Market Overview

The U.S. HIV drugs market is structurally unlike the global norm because revenue is driven by net price and payer mix rather than patient volume. The country has roughly 1.2 million people living with HIV, according to CDC estimates, and nearly all receive branded antiretroviral regimens. Gilead Sciences and ViiV Healthcare hold a majority of branded prescriptions, while generics serve mainly through Medicaid and government programs. Market value reached an estimated USD 22.6 billion in 2024, making the United States the largest single national market for HIV drugs worldwide.

Unlike markets where generics dominate, U.S. demand is segmented across commercial insurers, Medicare Part D, Medicaid managed care, and AIDS Drug Assistance Programs. Each payer applies different formulary rules, rebate arrangements, and prior authorization requirements, so market access determines revenue more than list price. The 340B Drug Pricing Program further reshapes the economics by allowing eligible covered entities to purchase at discounted prices. Ryan White HIV/AIDS Program funding, exceeding USD 2.5 billion annually, anchors safety-net demand for lower-cost regimens across Southern and urban clinics.

Growth Drivers in U.S. HIV Drug Demand

The Ending the HIV Epidemic in the U.S. initiative, launched by HHS in 2019, targets a 90 percent reduction in new infections by 2030 and channels funding into testing and PrEP. Federal policy has expanded PrEP access through the Affordable Care Act's preventive services mandate, which requires no-cost-sharing coverage for FDA-approved PrEP products. The FDA's June 2025 approval of Gilead's Yeztugo, a twice-yearly lenacapavir injection for PrEP, extends this demand into long-acting formats with high persistence and recurring revenue potential.

Demographic shifts add prescription volume. People with HIV are living longer on treatment, and CDC data show adults aged 50 and older now make up nearly half of all people living with the virus. Rising diagnoses among Black and Hispanic men who have sex with men in Southern states sustain new-start demand. Because antiretroviral therapy is lifelong, a growing prevalent population converts into continuous prescription revenue rather than one-time sales.

Market Restraints and Entry Barriers

Entry is constrained by the Medicaid Drug Rebate Program, which requires manufacturers to pay a basic rebate of 23.1 percent of average manufacturer price on brand products, with additional inflation penalties and best-price obligations. Pharmacy benefit managers, notably CVS Caremark and Express Scripts, hold formulary leverage that excludes new entrants unless rebate offers match incumbent contracts. Patent thickets around integrase inhibitors and Paragraph IV litigation under the Hatch-Waxman Act delay generic entry by several years.

Regulatory and compliance hurdles are substantial. Foreign-manufactured products require a designated U.S. agent, an FDA pre-approval inspection, and establishment registration before an NDA or ANDA review can conclude. Ryan White and ADAP programs maintain their own formularies, so a federally approved product can still face state-level exclusion. Restrictions on 340B contract pharmacy arrangements complicate direct-to-patient distribution, and incumbents' long-term clinical datasets reinforce prescriber habits that new entrants must overcome.

Market Opportunities in U.S. HIV Therapeutics

Long-acting injectables represent the clearest near-term opening. Cabenuva and Apretude require clinic administration, creating demand for specialty pharmacy and infusion-capable clinic networks that are underserved in rural Southern counties. Analyst estimates place the addressable pool for long-acting formulations at roughly 300,000 patients by 2030, concentrated in Medicaid and Ryan White populations where adherence support is already funded.

Opportunity also exists in older regimens for government buyers. Efavirenz-based combinations and tenofovir disoproxil generics dominate low-cost tenders, leaving room for quality-certified suppliers in 340B and state ADAP tender channels. Pediatric and adolescent fixed-dose formulations remain under-supplied relative to adult products, offering a defensible niche for suppliers willing to pursue pediatric labeling and dosing data.

Market at a Glance

Leading Market Participants

• Gilead Sciences
• ViiV Healthcare
• Merck
• AbbVie
• Janssen Pharmaceuticals
• Bristol Myers Squibb
• Teva Pharmaceuticals
• Viatris
• Camber Pharmaceuticals
• Aurobindo Pharma USA

Regulatory and Policy Environment

The FDA's Division of Antiviral Products reviews HIV new drug applications under PDUFA goals, typically ten months for standard review and six months for priority review, while the Office of Generic Drugs handles ANDAs under the Hatch-Waxman Act of 1984. The Inflation Reduction Act of 2022 caps Medicare Part D out-of-pocket spending at USD 2,000 from 2025 and authorizes CMS to negotiate prices for selected drugs, with eligibility arriving seven years after approval for small molecules.

The 340B Drug Pricing Program, administered by HRSA, requires manufacturers with Medicaid agreements to offer discounted prices to eligible covered entities. The Ryan White HIV/AIDS Treatment Extension Act of 2009 governs the federal Ryan White funding structure, and the Ending the HIV Epidemic initiative is coordinated through HHS. The FTC enforces against pay-for-delay settlements, while state Medicaid agencies set preferred drug lists through annual cycles that determine access for the largest publicly insured patient group.

Long-Term Outlook for HIV Drugs in the United States

By 2032, the U.S. HIV drugs market is forecast to reach USD 33.4 billion at a 5.0 percent CAGR. Oral single-tablet regimens will remain the majority of prescriptions, but their share will decline as long-acting injectables and PrEP products capture new starts and switch patients. Revenue growth will concentrate in products with durable adherence profiles and strong Medicaid contract positions.

Price pressure will intensify in the late 2020s. Compound patents on current single-tablet regimens begin expiring toward the end of the decade, setting up generic entry in the early 2030s. Companies that secure long-acting channel access and government program contracts before that transition will hold the stronger position in the post-patent market.